TABLE 2.

Efficacy of PT2385 for previously treated advanced clear cell renal cell carcinoma (NCT02293980).

Number of patients	Dose	Primary end‐point	Treatment line	MTD	Efficacy
					CR	PR	SD	PD	NE	ORR (%)	DCR (%)
51	100–1800 mg, twice daily	MTD	2nd line or beyond	Not identified	1	6	26	17	1	14	66

Abbreviations: CR, complete response; DCR, disease control rate; MTD, maximum tolerated dose; NE, not evaluable; ORR, objective response rate; PD, progressive disease; PR, partial response; SD, stable disease.